Pharmaceutical - tofacitinib

Filter

Current filters:

tofacitinib

Popular Filters

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

09-10-2013

Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study

08-07-2013

Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

Newly approved tofacitinib slows rheumatoid arthritis joint damage

24-01-2013

A Phase III clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression…

Anti-Arthritics/RheumaticsPfizerPharmaceuticalResearchtofacitinibXeljanz

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

07-11-2012

Having in the summer put back its "action date" due to a request for additional analysis of the existing…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinibXeljanz

FDA puts back action date on Pfizer's tofacitinib by three months

22-08-2012

Pfizer (NYSE: PFE), the world's largest drugmaker by sales, yesterday revealed that the US Food and Drug…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinib

Pfizer RA drug candidate tofacitinib shows promise in ulcerative colitis

16-08-2012

Patients with moderately to severely active ulcerative colitis treated with drug behemoth Pfizer's (NYSE…

Gastro-intestinalsPfizerPharmaceuticalResearchtofacitinib

Positive new data for Pfizer's tofacitinib; possible regulatory delay

01-08-2012

Pfizer (NYSE:PFE), the world's largest drugmaker by sales, yesterday released positive top-line results…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationResearchtofacitinib

FDA advisory backs Pfizer's tofacitinib for RA

10-05-2012

The US Food and Drug Administration's Arthritis Advisory Committee yesterday voted eight to two to recommend…

Anti-Arthritics/RheumaticsNorth AmericaPfizerPharmaceuticalRegulationtofacitinib

Ulcerative colitis drug market to reach $3 billion by 2020

02-05-2012

The ulcerative colitis drug market will experience moderate growth over the next decade, increasing from…

Gastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi Injectiontofacitinibvedolizumab

Unexpectedly strong data for Galapagos rheumatoid arthritis drug candidate

24-11-2011

Shares of Belgium-based biotech firm Galapagos (Euronext: GLPG) jumped 22% on Tuesday and a further 12%…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibGalapagosPfizerPharmaceuticalResearchtofacitinib

Many European dermatologists want more post-marketing data before Rxing Pfizer’s Janus

12-09-2011

At least half of surveyed dermatologists across the EU5 (France, Germany, Italy, Spain and the UK) will…

BiotechnologyDermatologicalsEuropeJanusMarkets & MarketingPfizerPharmaceuticaltofacitinib

Back to top